Lead Sponsor

KU Leuven

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
•2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)
•3. ECOG from 0 to 2
•4. Patient with stage IV ILC, either de novo or after prior (curative) treatment for early ILC. Histological subtype confirmed on primary tumor or on metastatic tissue. Patients that are diagnosed with stage IV breast cancer that have a mixed ILC/IBC-NST histology of the primary tumor (mixed histology within the same primary lesion) will also be able to participate and will be analyzed in an exploratory cohort.
•5. Confirmation of hormone receptor positive (HR+)/HER2- disease either on new biopsy or archival tissue (e.g. primary tumor)
•6. Multifocal or bilateral disease is allowed if all evaluated foci present with HR+/HER2- ILC
•7. Starting first line of treatment for metastatic ILC

•1. Presence of a contraindication to perform WB-DWI/MRI
•2. Presence of severe claustrophobia
•3. Presence of a contraindication to use IV contrast for CT or PET/CT (e.g. allergy, severe renal failure) in case a non-contrast PET/CT cannot be performed
•4. Patients considered to have oligometastatic disease who are expected to undergo locoregional treatment
•5. Presence of other malignancies in recent medical history (\<5 years)
•6. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive
•7. Adults who are the subject of a legal protection measure or who are unable to express their consent.

Related studies

NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more

NCT01953588 · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, and more

NCT04551495 · Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, and more

NCT01706432 · Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, and more

NCT01688388 · Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma, and more

Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses